Coherus BioSciences (CHRS) Misses Q3 EPS by 22c, Misses on Revenue
Tweet
Share
E-mailGet Alerts CHRS Hot Sheet
Price: $1.45 +0.69%
EPS Growth %: +23.5%
Financial Fact:
Gain from sale of office premises: 0
Today's EPS Names:
CRMT, More
EPS Growth %: +23.5%
Financial Fact:
Gain from sale of office premises: 0
Today's EPS Names:
CRMT, More
Join SI Premium – FREE
Coherus BioSciences (NASDAQ: CHRS) reported Q3 EPS of ($0.96), $0.22 worse than the analyst estimate of ($0.74). Revenue for the quarter came in at $45.4 million versus the consensus estimate of $57.27 million.
For earnings history and earnings-related data on Coherus BioSciences (CHRS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Trump said he was unaware of his earnings from crypto
- RBC Capital Downgrades Bucher Industries AG (BUCN:SW) (BCHHF) to Sector Perform
- Danone SA (BN:FP) (DANOY) PT Raised to EUR63 at Deutsche Bank
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
